Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

immunisation

- PMLiVE

Pfizer/BioNTech reach vaccine supply agreement with COVAX

Up to 40 million doses will be supplied to the international vaccine-sharing facility

- PMLiVE

WHO’s director-general deems vaccine nationalism a “catastrophic moral failure”

Tedros Adhanom Ghebreyesus warns bilateral deals could threaten COVAX facility

- PMLiVE

WHO advises both doses of Pfizer/BioNTech’s COVID-19 vaccine within a 21-28 day schedule

Recommendations made by the WHO's Strategic Advisory Group of Experts on Immunization

- PMLiVE

WHO set to review Pfizer/BioNTech COVID-19 vaccine for emergency use listing

Follows approval for emergency use in the UK yesterday

- PMLiVE

WHO director-general says urgent support is needed for COVAX facility

Immediate funding support totalling $4.3bn is required

Article

How will COVID-19 affect uptake of vaccinations against other diseases?

Research Partnership

- PMLiVE

Russia submits COVID-19 vaccine to WHO for emergency use listing

Russia became first country to grant approval to a COVID-19 vaccine in August

China flag thumb

Experimental Chinese COVID-19 vaccine is safe, according to researchers

Safety data was published on pre-print server medRxiv

- PMLiVE

WHO’s director-general says COVID-19 vaccine may be available by year-end

Remarks were made at a WHO executive board meeting earlier this week

- PMLiVE

Widespread COVID-19 vaccinations not expected until mid-2021, says WHO

Potential candidates must prove robust efficacy and safety first

EU flag

EU to contribute €400m to WHO’s COVID-19 vaccine facility

Contribution will go towards ensuring equitable access to COVID-19 vaccines

- PMLiVE

EU aims to vaccinate 40% of population in initial COVID-19 blueprint

Target is double the goal set by the World Health Organization

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links